For use in healthy cattle, including pregnant cows and heifers, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis (IBR), bovine virus diarrhea (BVD Type 1 and BVD Type 2), parainfluenza Type 3 (PI3), and bovine respiratory syncytial (BRSV) viruses and Leptospira canicola, grippotyphosa, hardjo-bovis, icterohaemorrhagiae, and pomona. For use in calves vaccinated at four weeks of age, or older, as an aid in the prevention of hardjo-bovis kidney colonization, and as an aid in preventing urinary shedding and reproductive tract infection for 12 months. Produced from non-cytopathic (BVD Type 1 and BVD Type 2) and cytopathic (BVD Type 1) isolates. Vaccinated animals subsequently exposed to L. borgpetersenii serovar hardjo (type hardjo-bovis) have been shown to clear renal infections within 8 weeks of exposure. Administer 5 mL subcutaneously. In accordance with Beef Quality Assurance guidelines, this product should be administered subcutaneously (under the skin) in the neck. Revaccinate in 4-5 weeks. Vaccinate dairy cows at dry-off. Revaccinate annually or as recommended by your veterinarian.